COMPARISON

BPC-157 vs Icatibant

5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.

Answer

BPC-157 is authorised or registered in 0 and Icatibant in 10 of the 10 registers read. BPC-157: highest phase Phase 2. Icatibant: highest phase Phase 3 (3 phase 3 trials, 0 with posted results). 0 registered trials include both.

States no view on which is preferable, safer or more effective. Not medical advice.

BPC-157Icatibant
Registered trials
differs
4
clinicaltrials.gov · 2026-10-03
37
clinicaltrials.gov · 2026-10-03
FDA label
differs
Not checked
no record of "fdaLabel" for bpc-157
FDA-approved: SAJAZIR
openfda · 2026-10-03T17:23:44.062Z
EU authorisation
differs
Nothing on record
ema read 2026-08-31
Authorised
ema · 2026-10-03
EU authorised on
differs
Not checked
no record of "authorisedOn" for bpc-157
2008-07-11
ema · 2026-10-03
ATC code
differs
Not checked
no record of "atcCode" for bpc-157
B06AC02
ema · 2026-10-03

SIDE EFFECTS

Most common side effects, each beside its own placebo

Side effectBPC-157placeboIcatibantplacebo
Hereditary angioedema--18.1%18.7%
Headache--10.1%6.7%

Trial register BPC-157: 0 placebo-controlled trials; Icatibant: 4. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. BPC-157 side effects · Icatibant side effects

LEGAL STATUS

Approval in each country read

CountryBPC-157IcatibantRegister
United StatesNot on the registerFDA-approvedRegulator FDA
European UnionNot on the registerAuthorisedRegulator EMA
United KingdomNot on the registerAuthorisedRegulator MHRA
CanadaNot on the registerAuthorisedRegulator Health Canada
AustraliaStatus unknownRegistered TGA
SwitzerlandNot on the registerAuthorisedRegulator Swissmedic
BrazilNot on the registerRegistadoRegulator ANVISA
SerbiaNot on the registerAuthorisedRegulator ALIMS
SingaporeNot on the registerRegisteredRegulator HSA
TurkeyNot on the registerRuhsatliRegulator TITCK

Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.